Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 11, 2017 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will provide a corporate overview and participate in a fireside chat, led by Joanna Horobin, M.B. Ch.B., Idera’s Chief Medical Officer at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 9:45 a.m. Eastern Time at the Le Parker Meridien Hotel in New York City.

Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com.  Archived versions will also be available on the Company’s website after the event for 90 days. 

About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484‐639‐7235 (mobile)
[email protected]